Needham analyst Serge Belanger has maintained their bullish stance on BCRX stock, giving a Buy rating today.
Serge Belanger has given his Buy rating due to a combination of factors that highlight BioCryst’s potential for growth and profitability. One of the key reasons is the upward revision of Orladeyo’s 2025 sales guidance, which is expected to reach between $535 million and $550 million. This increase is attributed to the positive impact of the Inflation Reduction Act (IRA), which has led to lower copayments and improved prescription rates among Medicare patients.
Additionally, the company has reported encouraging results from its pediatric Orladeyo trial, which will support a New Drug Application filing later in 2025. Furthermore, BioCryst is expected to release initial data from its BCX17725/Netherton syndrome and avoralstat/DME programs by the end of 2025. Despite recent fluctuations in stock performance, Belanger maintains a Buy rating with a price target of $15, as the current valuation does not fully reflect the company’s top-line growth and long-term profitability potential.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.